JAZZ
Jazz Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
6.50 / 10
Outperform
Analyst consensus is overwhelmingly bullish with a Strong Buy rating from two analysts, supported by a 5.22 historical weighted rating. Fund flow evaluation is strong (7.78/10), with positive trends in block, small, and extra-large inflows, although medium and large inflows are negative. The sentiment score of 6.5 indicates an Outperform stance, reflecting robust fund flow characteristics and a positive analyst outlook.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-12
InstitutionNeedham
Times predicted9
Historical Win Rate55.6%
What is the analyst consensus for JAZZ?
- JAZZ holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.50/10 (Outperform).
